A215600 Stock Overview
Develops and commercializes oncolytic immunotherapy products in South Korea. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
SillaJen, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩2,535.00 |
| 52 Week High | ₩6,620.00 |
| 52 Week Low | ₩2,340.00 |
| Beta | -0.083 |
| 1 Month Change | -13.92% |
| 3 Month Change | -8.81% |
| 1 Year Change | -55.91% |
| 3 Year Change | n/a |
| 5 Year Change | -85.35% |
| Change since IPO | -80.27% |
Recent News & Updates
Is SillaJen (KOSDAQ:215600) Using Too Much Debt?
Nov 04
Is SillaJen (KOSDAQ:215600) A Risky Investment?
Jul 05Shareholder Returns
| A215600 | KR Biotechs | KR Market | |
|---|---|---|---|
| 7D | 1.2% | 1.5% | -1.5% |
| 1Y | -55.9% | 3.9% | -10.9% |
Return vs Industry: A215600 underperformed the KR Biotechs industry which returned 3.9% over the past year.
Return vs Market: A215600 underperformed the KR Market which returned -10.9% over the past year.
Price Volatility
| A215600 volatility | |
|---|---|
| A215600 Average Weekly Movement | 7.5% |
| Biotechs Industry Average Movement | 8.8% |
| Market Average Movement | 6.6% |
| 10% most volatile stocks in KR Market | 12.8% |
| 10% least volatile stocks in KR Market | 3.4% |
Stable Share Price: A215600 has not had significant price volatility in the past 3 months compared to the KR market.
Volatility Over Time: A215600's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2006 | 43 | Jaekyung Kim | www.sillajen.com |
SillaJen, Inc. develops and commercializes oncolytic immunotherapy products in South Korea. Its lead product is Pexa-Vec for the treatment of advanced liver cancer. The company also develops BAL0891, a dual TTK/PLK inhibitor; SJ-600 to improve the intravenous administration efficiency of anticancer viruses; JX-970 for the treatment of tumor tissues; and JX-900 is a series of modified vaccinia vaccine.
SillaJen, Inc. Fundamentals Summary
| A215600 fundamental statistics | |
|---|---|
| Market cap | ₩348.04b |
| Earnings (TTM) | -₩25.80b |
| Revenue (TTM) | ₩1.23b |
283.0x
P/S Ratio-13.5x
P/E RatioIs A215600 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A215600 income statement (TTM) | |
|---|---|
| Revenue | ₩1.23b |
| Cost of Revenue | ₩2.48b |
| Gross Profit | -₩1.25b |
| Other Expenses | ₩24.54b |
| Earnings | -₩25.80b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -187.89 |
| Gross Margin | -101.90% |
| Net Profit Margin | -2,097.68% |
| Debt/Equity Ratio | 6.7% |
How did A215600 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/02 02:20 |
| End of Day Share Price | 2025/01/02 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
SillaJen, Inc. is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Wan Ku | NH Investment & Securities Co., Ltd. |
| Kidal Bae | Shinhan Investment Corp. |